Abigail Jenkins
President & CEO
Claimed by owner Gamida Cell
Former names:
Cellular and Immune Therapies
Public on NASDAQ Oct, 2018
Gamida Cell
www.sponser.co.il
•
Apr 20, 2023
אחרי הזינוק: גמידה סל תגייס 23 מיליון דולר, כת”ב תדולל
en.globes.co.il
•
Apr 18, 2023
Gamida Cell surges after FDA approves cancer treatment
www.businesswire.com
•
Apr 17, 2023
Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
www.businesswire.com
•
Nov 3, 2022
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
www.businesswire.com
•
Sep 29, 2022
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
www.businesswire.com
•
Aug 10, 2022
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
www.businesswire.com
•
Aug 1, 2022
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
www.businesswire.com
•
Jun 2, 2022
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
www.businesswire.com
•
Jan 19, 2022
Gamida Cell Provides Update on Omidubicel BLA Submission
www.businesswire.com
•
Jun 7, 2021
Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update
www.businesswire.com
•
Mar 1, 2021
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
www.calcalistech.com
•
Feb 16, 2021
Gamida Cell announces $75 million financing with Highbridge Capital Management
www.sponser.co.il
•
Dec 20, 2020
גמידה סל מצטרפת למדד הביוטכנולוגיה של ה-Nasdaq
www.businesswire.com
•
Dec 16, 2020
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
www.biospace.com
•
Oct 13, 2020
Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration BioSpace
www.jpost.com
•
Oct 11, 2020
https://www.jpost.com/health-science/israeli-company-sees-promising-results-in-blood-cancer-treatment-trial-645311
www.businesswire.com
•
Sep 3, 2020
Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September
en.globes.co.il
•
May 19, 2020
Gamida Cell raises $60m at 24% discount
en.globes.co.il
•
May 12, 2020
Bone marrow co Gamida Cell reports positive Phase III results
en.globes.co.il
•
Jul 1, 2019
Gamida Cell raises $35m;share plummets 30%
www.pharmaceutical-business-review.com
•
Jun 20, 2019
Gamida Cell, Lonza establish commercial manufacturing agreement for omidubicel - Pharmaceutical Business review
www.biospace.com
•
Jun 5, 2019
Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer BioSpace
www.businesswire.com
•
May 31, 2019
Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting
www.businesswire.com
•
Mar 21, 2019
Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
www.biospace.com
•
Feb 21, 2019
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting BioSpace
www.biospace.com
•
Feb 19, 2019
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells BioSpace
lymphomanewstoday.com
•
Jan 29, 2019
Gamida Cell, Be The Match BioTherapies Team Up on NiCord for Blood...
www.businesswire.com
•
Jan 24, 2019
Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
www.marketwatch.com
•
Jan 22, 2019
https://www.marketwatch.com/press-release/gamida-cell-and-be-the-match-biotherapies-announce-strategic-collaboration-2019-01-22
en.globes.co.il
•
Oct 28, 2018
Gamida Cell raises $50m in Nasdaq IPO
en.globes.co.il
•
Oct 17, 2018
Novartis to invest in $60m Gamida Cell Nasdaq IPO
www.calcalistech.com
•
Sep 30, 2018
Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO
en.globes.co.il
•
Sep 2, 2018
Gamida Cell files for Nasdaq IPO
www.gamida-cell.com
•
Aug 6, 2018
Press Releases - Investors - Gamida Cell Ltd.
www.globes.co.il
•
Dec 13, 2017
Gamida Cell reports positive cancer drug trial
www.prnewswire.com
•
Jul 20, 2017
Gamida Cell Announces $3.5 Million Grant from the Israeli Government
www.prnewswire.com
•
Jul 10, 2017
Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
www.reuters.com
•
Jun 19, 2017
Israel's Gamida Cell raises $40 million for bone marrow trial
www.globes.co.il
•
Mar 8, 2017
Investment fund leading $30m Gamida Cell round
www.gamida-cell.com
•
Dec 6, 2016
http://www.gamida-cell.com/press_item.asp?ID=71&t=Gamida-Cell-Presents-Positive-Data-From-Phase-1/2-Study-of-NiCord%C2%AE-as-a-Curative-Treatment-for-Sickle-Cell-Disease-at-ASH-2016
www.geektime.co.il
•
Oct 14, 2015
גיוס: Gamida Cell הישראלית מגייסת 15 מיליון דולר מ-Novartis
www.finsmes.com
•
May 15, 2012
Gamida Cell Closes $10m Series E Financing - FinSMEs
en.globes.co.il
•
Sep 27, 2006
Gamida Cell raises $16m in fourth financing round
About
Gamida Cell is pioneering a diverse approach to cellular therapy that utilizes nicotinamide (NAM) to expand multiple cell types — including stem cells and natural killer (NK) cells — while maintaining their original phenotype and potency. When applied to umbilical cord blood–derived cells in the production of our investigational omidubicel product for allogeneic stem cell transplant, NAM-enabled cells have improved clinical measures such as engraftment time and infection rate, potentially leading to better outcomes for patients.
Gamida Cell has developed a reliable, scalable and GMP-compliant culture method for NAM expansion that yields highly functional NK cells. These cells have demonstrated ability to kill cancerous cells in both animal models and clinical trials, and are being developed in both unmodified and genetically engineered forms.
The company received FDA approval for Omisirge (omidubicel-onlv), an allogenic cell therapy to reduce the risk of infection in blood cancer patients.
Gamida Cell has developed a reliable, scalable and GMP-compliant culture method for NAM expansion that yields highly functional NK cells. These cells have demonstrated ability to kill cancerous cells in both animal models and clinical trials, and are being developed in both unmodified and genetically engineered forms.
The company received FDA approval for Omisirge (omidubicel-onlv), an allogenic cell therapy to reduce the risk of infection in blood cancer patients.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
GDA-201, Omisirge
Geographic markets
United States
Funding
Total Funding
$310.02M
Market Cap
$170M
Last Funding
$75M
Funding Stage
Total Rounds
11
Investors
12
News
(43)
www.sponser.co.il
•
Apr 20, 2023
אחרי הזינוק: גמידה סל תגייס 23 מיליון דולר, כת”ב תדולל
en.globes.co.il
•
Apr 18, 2023
Gamida Cell surges after FDA approves cancer treatment
www.businesswire.com
•
Apr 17, 2023
Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
www.businesswire.com
•
Nov 3, 2022
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
www.businesswire.com
•
Sep 29, 2022
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
www.businesswire.com
•
Aug 10, 2022
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
www.businesswire.com
•
Aug 1, 2022
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
www.businesswire.com
•
Jun 2, 2022
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
www.businesswire.com
•
Jan 19, 2022
Gamida Cell Provides Update on Omidubicel BLA Submission
www.businesswire.com
•
Jun 7, 2021
Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update
www.businesswire.com
•
Mar 1, 2021
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
www.calcalistech.com
•
Feb 16, 2021
Gamida Cell announces $75 million financing with Highbridge Capital Management
www.sponser.co.il
•
Dec 20, 2020
גמידה סל מצטרפת למדד הביוטכנולוגיה של ה-Nasdaq
www.businesswire.com
•
Dec 16, 2020
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
www.biospace.com
•
Oct 13, 2020
Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration BioSpace
www.jpost.com
•
Oct 11, 2020
https://www.jpost.com/health-science/israeli-company-sees-promising-results-in-blood-cancer-treatment-trial-645311
www.businesswire.com
•
Sep 3, 2020
Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September
en.globes.co.il
•
May 19, 2020
Gamida Cell raises $60m at 24% discount
en.globes.co.il
•
May 12, 2020
Bone marrow co Gamida Cell reports positive Phase III results
en.globes.co.il
•
Jul 1, 2019
Gamida Cell raises $35m;share plummets 30%
www.pharmaceutical-business-review.com
•
Jun 20, 2019
Gamida Cell, Lonza establish commercial manufacturing agreement for omidubicel - Pharmaceutical Business review
www.biospace.com
•
Jun 5, 2019
Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer BioSpace
www.businesswire.com
•
May 31, 2019
Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting
www.businesswire.com
•
Mar 21, 2019
Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
www.biospace.com
•
Feb 21, 2019
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting BioSpace
www.biospace.com
•
Feb 19, 2019
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells BioSpace
lymphomanewstoday.com
•
Jan 29, 2019
Gamida Cell, Be The Match BioTherapies Team Up on NiCord for Blood...
www.businesswire.com
•
Jan 24, 2019
Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
www.marketwatch.com
•
Jan 22, 2019
https://www.marketwatch.com/press-release/gamida-cell-and-be-the-match-biotherapies-announce-strategic-collaboration-2019-01-22
en.globes.co.il
•
Oct 28, 2018
Gamida Cell raises $50m in Nasdaq IPO
en.globes.co.il
•
Oct 17, 2018
Novartis to invest in $60m Gamida Cell Nasdaq IPO
www.calcalistech.com
•
Sep 30, 2018
Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO
en.globes.co.il
•
Sep 2, 2018
Gamida Cell files for Nasdaq IPO
www.gamida-cell.com
•
Aug 6, 2018
Press Releases - Investors - Gamida Cell Ltd.
www.globes.co.il
•
Dec 13, 2017
Gamida Cell reports positive cancer drug trial
www.prnewswire.com
•
Jul 20, 2017
Gamida Cell Announces $3.5 Million Grant from the Israeli Government
www.prnewswire.com
•
Jul 10, 2017
Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
www.reuters.com
•
Jun 19, 2017
Israel's Gamida Cell raises $40 million for bone marrow trial
www.globes.co.il
•
Mar 8, 2017
Investment fund leading $30m Gamida Cell round
www.gamida-cell.com
•
Dec 6, 2016
http://www.gamida-cell.com/press_item.asp?ID=71&t=Gamida-Cell-Presents-Positive-Data-From-Phase-1/2-Study-of-NiCord%C2%AE-as-a-Curative-Treatment-for-Sickle-Cell-Disease-at-ASH-2016
www.geektime.co.il
•
Oct 14, 2015
גיוס: Gamida Cell הישראלית מגייסת 15 מיליון דולר מ-Novartis
www.finsmes.com
•
May 15, 2012
Gamida Cell Closes $10m Series E Financing - FinSMEs
en.globes.co.il
•
Sep 27, 2006
Gamida Cell raises $16m in fourth financing round
The Team
(5)
AJ
SL
Shai Lankry
CFO
RS
Ronit Simantov
Chief Medical Officer
MK
Michele Korfin
Chief Operating Officer & Chief Commercial Officer
VM
Vladimir Melnikov
SVP Global Operations and Manufacturing
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
$50M
Oct 2018
Stock Exchange
NASDAQ
Valuation
$210M
$50M
Public Offering
$35M
Jul 2019
Stock Exchange
NASDAQ
Valuation
Undisclosed
$35M
Private Equity Funding
A Round
$6.37M
May 2000
1 Investors
$6.37M
B Round
$9.75M
Oct 2001
3 Investors
$9.75M
D Round
$16M
Sep 2006
5 Investors
$16M
E Round
$10M
May 2012
6 Investors
$10M
F Round
$40M
Jun 2017
4 Investors
$40M
Post-IPO Equity Funding
$60M
May 2020
$60M
Post-IPO Equity Funding
$75M
Feb 2021
1 Investors
$75M
Non-Equity Funding
Grant
$4.4M
May 2016
1 Grantors
$4.4M
Grant
$3.5M
Jul 2017
1 Grantors
$3.5M
Media gallery
(0)Locations
Israel
Leshem St 12, Kiryat Gat, Israel
Offices Abroad
673 Boylston Street, Boston, MA, USA
Locations
Israel
Leshem St 12, Kiryat Gat, Israel
Offices Abroad
673 Boylston Street, Boston, MA, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,